NDI draft guidance

©Getty Images - jetacomputer

Guest article

CRN: Don’t Sell Out DSHEA for CBD

By By Steve Mister, President & CEO, Council for Responsible Nutrition

We all want an expedient solution to the stalemate with FDA over the legal status of cannabidiol (CBD), but the call to allow FDA to set a maximum safe level for CBD is antithetical to the law governing dietary supplements, DSHEA.

Nuseed Nutritional uses a genetically modified form of canola as the raw material for its plant-based omega-3 ingredient. ©Getty Images - alexxx1981

GMO plant-based omega-3 approved as NDI

By Hank Schultz

Nuseed Nutritional US has announced its omega-3 ingredient derived from a genetically modified canola strain has successfully completed a New Dietary Ingredient Notification with FDA.

©Getty Images - Ildo Frazen

FDA lists NDI update among priorities for coming year

By Hank Schultz

Publishing a revised version of the NDI Draft Guidance has made a list of FDA priorities for the coming year. Industry observers welcomed the news, but questioned how much impact it might have if enforcement priorities remain as they are.

©Getty Images - serggn

CRN's petition sets 180-day deadline for resolution of NAC issue

By Hank Schultz

The Council for Responsible Nutrition has filed a citizen’s petition with FDA requesting that the Agency reverse its decision that the ingredient NAC is not legal for use in dietary supplements. CRN states that FDA’s ruling on the matter, voiced in warning...

CRN’s Mister on the best solution for CBD, DSHEA 2.0, and more

CRN’s Mister on the best solution for CBD, DSHEA 2.0, and more

By Stephen Daniells

The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act represents ‘the best way’ to deal with the hemp-CBD issue for dietary supplements, says CRN’s Steve Mister, and once that’s clarified then the FDA and industry can address...

NPA’s Fabricant on CBD, NDI-related import alerts, and banned stimulants

NPA’s Fabricant on CBD, NDI-related import alerts, and banned stimulants

By Stephen Daniells

Efforts to move the needle on hemp-CBD at the Federal level are slow, and upcoming exits of key personnel at FDA are unlikely to affect progress much, says NPA’s Dr Daniel Fabricant. “In some ways I think FDA likes the status quo,” he tells NutraIngredients-USA.

© eakgrunge / Getty Images

FDA seizes Chinese imports over NDI status

By Hank Schultz

The US Food and Drug Administration has issued an import alert and seized products from two firms that were deemed to be offering New Dietary Ingredients that have not gone through the notification process.

Follow us

Products

View more

Webinars